undamentalytics Newsletter

Definium Therapeutics, Inc. valuation and forecast

Explore the models for Definium Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Definium Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

19 analysts, Oct 2026
Buy19100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202651419
  2. Sep 202641418
  3. Aug 202641418
  4. Jul 202641317

Counts of recommendations published by analysts covering Definium Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

DFTX valuation questions

How does Fundamentalytics value Definium Therapeutics, Inc.?
We use the models that fit Definium Therapeutics, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Definium Therapeutics, Inc.